WHO 2016 Classification of gliomas
P Wesseling, D Capper - Neuropathology and applied …, 2018 - Wiley Online Library
Gliomas are the most frequent intrinsic tumours of the central nervous system and
encompass two principle subgroups: diffuse gliomas and gliomas showing a more …
encompass two principle subgroups: diffuse gliomas and gliomas showing a more …
Pediatric low-grade glioma in the era of molecular diagnostics
Low grade gliomas are the most frequent brain tumors in children and encompass a
spectrum of histologic entities which are currently assigned World Health Organisation …
spectrum of histologic entities which are currently assigned World Health Organisation …
Central nervous system cancers, version 3.2020, NCCN clinical practice guidelines in oncology
LB Nabors, J Portnow, M Ahluwalia, J Baehring… - Journal of the National …, 2020 - jnccn.org
The NCCN Guidelines for Central Nervous System (CNS) Cancers focus on management of
adult CNS cancers ranging from noninvasive and surgically curable pilocytic astrocytomas …
adult CNS cancers ranging from noninvasive and surgically curable pilocytic astrocytomas …
Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma
PURPOSE Diffuse gliomas are malignant brain tumors that include lower-grade gliomas
(LGGs) and glioblastomas. Transformation of low-grade glioma into a higher tumor grade is …
(LGGs) and glioblastomas. Transformation of low-grade glioma into a higher tumor grade is …
Survival in glioblastoma: a review on the impact of treatment modalities
PD Delgado-López, EM Corrales-García - Clinical and Translational …, 2016 - Springer
Glioblastoma (GBM) is the most common and lethal tumor of the central nervous system. The
natural history of treated GBM remains very poor with 5-year survival rates of 5%. Survival …
natural history of treated GBM remains very poor with 5-year survival rates of 5%. Survival …
Sex differences in GBM revealed by analysis of patient imaging, transcriptome, and survival data
W Yang, NM Warrington, SJ Taylor… - Science translational …, 2019 - science.org
Sex differences in the incidence and outcome of human disease are broadly recognized but,
in most cases, not sufficiently understood to enable sex-specific approaches to treatment …
in most cases, not sufficiently understood to enable sex-specific approaches to treatment …
Glioblastoma: pathology, molecular mechanisms and markers
K Aldape, G Zadeh, S Mansouri, G Reifenberger… - Acta …, 2015 - Springer
Recent advances in genomic technology have led to a better understanding of key
molecular alterations that underlie glioblastoma (GBM). The current WHO-based …
molecular alterations that underlie glioblastoma (GBM). The current WHO-based …
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic …
MJ van den Bent, B Baumert, SC Erridge… - The Lancet, 2017 - thelancet.com
Background The role of temozolomide chemotherapy in newly diagnosed 1p/19q non-co-
deleted anaplastic gliomas, which are associated with lower sensitivity to chemotherapy and …
deleted anaplastic gliomas, which are associated with lower sensitivity to chemotherapy and …
[HTML][HTML] IDH mutations in cancer and progress toward development of targeted therapeutics
L Dang, K Yen, EC Attar - Annals of Oncology, 2016 - Elsevier
ABSTRACT Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are key metabolic enzymes,
converting isocitrate to α-ketoglutarate (αKG). IDH1 and IDH2 mutations have been …
converting isocitrate to α-ketoglutarate (αKG). IDH1 and IDH2 mutations have been …
High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
R Stupp, M Brada, MJ Van Den Bent… - Annals of …, 2014 - annalsofoncology.org
The yearly incidence of malignant glioma is∼ 3–5/100 000 with a slight predominance in
males. Malignant glioma may develop at all ages, with the peak incidence being in the fifth …
males. Malignant glioma may develop at all ages, with the peak incidence being in the fifth …